Enveric Biosciences, INC Form 4 insider transactions

Enveric Biosciences' Chief Financial Officer, Kevin Michael Coveney, acquired 133,333 restricted stock units on June 1, 2026, as part of his compensation plan.

Enveric Biosciences reports a significant grant of restricted stock units to CEO Joseph Edward Tucker, with vesting over four years.

Director Frank Pasqualone acquired 18,518 shares of Enveric Biosciences common stock through a restricted stock grant.

Director Michael D. Webb acquired 18,518 shares of Enveric Biosciences, Inc. common stock through a restricted stock grant.

Enveric Biosciences, Inc. Director Marcus Schabacker reported the acquisition of 18,518 shares of common stock on June 1, 2026, under the company's 2020 Long-Term Incentive Plan.

Director George A. Kegler acquired 18,518 shares of Enveric Biosciences, Inc. common stock through a restricted stock grant.

Enveric Biosciences, Inc. reports a Form 4 filing detailing a transaction by Director Sheila DeWitt, acquiring 18,518 shares of common stock.

Peter J. Facchini, Chief Innovation Officer at Enveric Biosciences, Inc., reported a transaction involving restricted stock units.

Enveric Biosciences Director Sheila DeWitt was granted 7,633 restricted shares, with her total beneficial ownership adjusted for recent reverse stock splits.

Enveric Biosciences Director George A. Kegler received a restricted stock grant of 7,633 shares, with reported holdings adjusted for two recent reverse stock splits.

Enveric Biosciences Director Frank Pasqualone was granted 7,633 restricted common shares, with reported holdings adjusted for two recent reverse stock splits.

Enveric Biosciences Director Marcus Schabacker was granted 7,633 shares of restricted common stock, adjusted for recent reverse stock splits.

Enveric Biosciences' CEO, Joseph Edward Tucker, was granted 60,296 restricted stock units, with vesting contingent on continued employment, following a 1-for-12 reverse stock split.

Enveric Biosciences Director Michael D. Webb was granted 7,633 shares of common stock, with his total beneficial ownership adjusted for recent reverse stock splits.

Enveric Biosciences' CFO, Kevin Michael Coveney, was granted 40,198 restricted stock units following a 1-for-12 reverse stock split.

Kevin Coveney, CFO of Enveric Biosciences, reports acquisition of restricted stock units and adjustments to holdings following a reverse stock split.

Peter J. Facchini, Chief Innovation Officer of Enveric Biosciences, reports acquisition and disposal of common stock and restricted stock units.

CEO Joseph Edward Tucker reports receiving restricted stock units and an adjustment to his holdings following Enveric Biosciences' reverse stock split.

Sheila DeWitt, a director of Enveric Biosciences, acquired 27,845 shares of common stock on October 9, 2024, as part of a restricted stock grant.

Director George A. Kegler reports acquisition and disposal of Enveric Biosciences stock related to a restricted stock grant.

Director Marcus Schabacker reports acquisition and disposal of Enveric Biosciences (ENVB) common stock on October 9, 2024.

Director Michael Webb of Enveric Biosciences, Inc. reports the acquisition of 47,733 shares of common stock through a restricted stock grant.

Frank Pasqualone, a director at Enveric Biosciences, reported the acquisition and disposal of common stock related to a restricted stock grant.

Enveric Biosciences CEO Joseph Edward Tucker reports the acquisition of 161,633 shares of common stock through restricted stock units and the disposal of 335,829 shares.

Peter J. Facchini, Chief Innovation Officer of Enveric Biosciences, reports acquiring 40,000 shares of common stock and disposing of 130,856 shares.

Enveric Biosciences' CFO, Kevin Michael Coveney, was granted 100,000 restricted stock units (RSUs) under the company's 2020 Long-Term Incentive Plan.